Compounds and methods for treating diseases mediated by protease activated receptors
The invention relates to the use of a compound of Formula I for the treatment of protease-activated receptor mediated diseases by the administration of a compound of Formula I or a prodrug or metabolite thereof.
1. A method of treating a protease-activated receptor (PAR) mediated disease in a patient by administrating a therapeutically effective dose of compound selected from:
TABLE A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
23
24
25
26
wherein the PAR mediated disease is selected from acute Myocardial Infarction, acute occlusion following coronary angioplasty or stent placement thrombosis subsequent to or associated with a surgical procedure, and thrombosis associated with atrial fibrillation.
2. The method of claim 1 , wherein the patient is in need of inhibition of platelet activation.
3. The method of claim 1 , wherein the patient is in need of inhibition of thrombus formation.
4. The method of claim 1 , wherein said PAR mediated disease is acute Myocardial Infarction.
5. The method of claim 1 , wherein said PAR mediated disease is acute occlusion following coronary angioplasty or stent placement.
6. The method of claim 1 , wherein said PAR mediated disease is thrombosis subsequent to or associated with a surgical procedure.
7. The method of claim 1 , wherein said PAR mediated disease is thrombosis associated with atrial fibrillation.